BioCentury
ARTICLE | Company News

Goolsbee steps down as Sarepta chair

August 2, 2014 1:12 AM UTC

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said William Goolsbee stepped down as chairman but will remain a director. Director John Hodgman is serving as interim chair. Goolsbee has been a Sarepta director since October 2007 and became chair in June 2010. Hodgman -- EVP of finance and CFO of InterMune Inc. (NASDAQ:ITMN) -- has been on Sarepta's board since March 2004. Both Goolsbee and Hodgman are part of the board's audit and compensation committees. The only non-independent director on Sarepta's seven-member board is President and CEO Chris Garabedian.

The chairman change comes about a week after Sarepta terminated Arthur Krieg as SVP and CSO. Earlier this week, the Wall Street Journal also reported that the company had moved to limit Garabedian's role in discussions with FDA for eteplirsen ( AVI-4658). Sarepta plans to submit an NDA to FDA seeking accelerated approval of the compound to treat Duchenne muscular dystrophy (DMD) by year end (see BioCentury Extra, July 24). ...